Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>.

Human gene therapy·2026

Same author

Boosting the Activity of Melanoma-Targeting CAR-T Cells in the Presence of Citrate by the Application of Gluconate.

Pharmaceutics·2026

Same author

Blocking CD30 on CD19 CAR T cells augments their functional capacities against B-cell leukemia/lymphoma.

Frontiers in immunology·2026

Same author

The Tumour Immune Microenvironment as a Predictor of the Response to Neoadjuvant Therapy in Rectal Cancer.

Cancers·2026

Same author

Longitudinal plasma nano-proteomics reveals acute systemic responses to radiotherapy and predictive biomarkers of late toxicity.

Communications medicine·2026

Same author

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>.

Human gene therapy·2026

Search research articles

Related Experiment Video

Updated: May 19, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Chimeric antigen receptors for T-cell based therapy.

Eleanor J Cheadle¹, Vicky Sheard, Andreas A Hombach

¹Cell Therapy Group, Department of Medical Oncology, School of Cancer and Enabling Sciences, Manchester Academic Health Science Center, The University of Manchester, Manchester, UK.

Methods in Molecular Biology (Clifton, N.J.)

|August 22, 2012

Summary

This summary is machine-generated.

Chimeric antigen receptor (CAR) T-cells redirect T-cell functions to target cancer cells, bypassing traditional immune system restrictions. This technology enables genetic modification of human and mouse T-cells for enhanced adoptive T-cell therapy.

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Published on: August 18, 2023

Related Experiment Videos

Last Updated: May 19, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Published on: August 18, 2023

Area of Science:

Immunology
Cell Biology
Biotechnology

Background:

Chimeric antigen receptors (CARs) merge antibody-based targeting with T-cell signaling domains.
CARs enable T-cells to recognize specific antigens on target cells, independent of traditional antigen presentation pathways.
This approach circumvents HLA-restriction, broadening the scope of adoptive T-cell therapy.

Purpose of the Study:

To describe methods for generating CAR T-cells for functional testing.
To focus on the genetic modification of both human and mouse T-cells for CAR T-cell therapy.

Main Methods:

Genetic modification of human and mouse T-cells to express CARs.
Functional testing of generated CAR T-cells.

Main Results:

CAR T-cells can be generated from both human and mouse T-cells.
The targeting domain of the CAR dictates antigen specificity.
CAR T-cell strategy is applicable to nonclassical targets like carbohydrates.

Conclusions:

CAR T-cell technology offers a versatile platform for adoptive T-cell therapy.
Methods for generating and testing CAR T-cells are crucial for advancing this therapeutic strategy.
The ability to modify T-cells from different species expands the potential applications of CAR T-cell therapy.